Dr. Kate Hanham
Dr. Hanham has consulted for organizations ranging from start-up biotechnology to top ten pharmaceutical companies
Kate Hanham, Ph.D. is the president and founder of Mentara, Inc. Dr. Hanham has consulted for organizations ranging from start-up biotechnology to top ten pharmaceutical companies. She has provided strategic input at all stages of product development, designed and implemented clinical, regulatory and manufacturing strategies from early development through to a new drug application.
Dr. Hanham has acted as an advisor to Boards of Directors and served as an interim C level executive. She has held lead responsibilities in critical communications with the FDA and international regulatory agencies. She has also provided assessment of technology, product development, clinical and manufacturing operations for financial groups seeking to invest in biotechnology.
Dr. Hanham earned her Ph.D. in biochemistry at the University of Birmingham, England. Her academic career led to a faculty position at Yale University.
Dr. Hanham then moved into private industry where her work experience included Centocor, Repligen and Medimmune (Aviron) prior to founding her consulting company in 1996. Dr. Hanham’s background in infectious diseases, applied immunology and vaccine development has provided experience critical to organizations developing a variety of products, including monoclonal antibodies, HIV and other viral vaccines, immune modulating agents, small molecule therapeutics, diagnostics and devices.
Together with her team at Mentara, Dr. Hanham has provided effective support for numerous companies at all stages of development, including the establishment and management of logistics for complex global clinical trials and building and commissioning manufacturing and associated analytical test facilities.
Dr. Hanham and her Mentara team have designed, implemented and managed studies domestically and internationally.